Moleculin Biotech ASCO abstract on Annamycin cardiac safety shows no cardiotoxicity in 90 patients

Moleculin Biotech, Inc.

Abstract accepted for poster at 2026 ASCO Annual Meeting (May 29–June 2, Chicago).
Pooled safety analysis of 90 Annamycin patients; median cumulative dose 660 mg/m2.
No significant LVEF change from baseline (mean diff -0.12%, p=0.84); no dose correlation.
CEO highlights potential to provide anthracycline therapy without cardiotoxicity limits.
Company's Phase 1b/2 AML study previously showed 50% CR and median OS of 12.39 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.